These studies support the synergistic role of CKI in cancer treatment, aligning with our meta-analysis and economic evaluation results, thereby further demonstrating the effectiveness and economic feasibility of combining CKI with zoledronic acid in managing bone metastasis-induced cancer pain. The gene discussed is CHKA; the disease is cancer.